|
1
|
Lisio MA, Fu L, Goyeneche A, Gao ZH and
Telleria C: High-grade serous ovarian cancer: Basic sciences,
clinical and therapeutic standpoints. Int J Mol Sci. 20:9522019.
View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Bast RC Jr, Hennessy B and Mills GB: The
biology of ovarian cancer: New opportunities for translation. Nat
Rev Cancer. 9:415–428. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
3
|
Lengyel E: Ovarian cancer development and
metastasis. Am J Pathol. 177:1053–1064. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Ferlay J, Soerjomataram I, Dikshit R, Eser
S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer
incidence and mortality worldwide: Sources, methods and major
patterns in GLOBOCAN 2012. Int J Cancer. 136:E359–E386. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Matulonis UA, Sood AK, Fallowfield L,
Howitt BE, Sehouli J and Karlan BY: Ovarian cancer. Nat Rev Dis
Primers. 2:160612016. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kurman RJ, Carcangiu ML, Herrington CS and
Young RH: WHO Classification of Tumours of Female Reproductive
Organs. 4th edition. WHO; Geneva, Switzerland: 2014
|
|
7
|
Ohman AW, Hasan N and Dinulescu DM:
Advances in tumor screening, imaging, and avatar technologies for
high-grade serous ovarian cancer. Front Oncol. 4:3222014.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
National Cancer Institute Surveillance,
Epidemiology and End Results Program, . Cancer Stat Facts: Ovarian
Cancer. https://seer.cancer.gov/statfacts/html/ovary.htmlMay
26–2018
|
|
9
|
Gilbert L, Basso O, Sampalis J, Karp I,
Martins C, Feng J, Piedimonte S, Quintal L, Ramanakumar AV,
Takefman J, et al: Assessment of symptomatic women for early
diagnosis of ovarian cancer: Results from the prospective DOvE
pilot project. Lancet Oncol. 13:285–291. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Narod S: Can advanced-stage ovarian cancer
be cured? Nat Rev Clin Oncol. 13:255–261. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
The American College of Obstetricians and
Gynecologists, . Five Things Physicians and Patients Should
Question. Choosing Wisely; 2013
|
|
12
|
Menon U, Gentry-Maharaj A, Hallett R, Ryan
A, Burnell M, Sharma A, Lewis S, Davies S, Philpott S, Lopes A, et
al: Sensitivity and specificity of multimodal and ultrasound
screening for ovarian cancer, and stage distribution of detected
cancers: Results of the prevalence screen of the UK Collaborative
Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncol.
10:327–340. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Buys SS, Partridge E, Black A, Johnson CC,
Lamerato L, Isaacs C, Reding DJ, Greenlee RT, Yokochi LA, Kessel B,
et al: Effect of screening on ovarian cancer mortality: The
prostate, lung, colorectal and ovarian (PLCO) cancer screening
randomized controlled trial. JAMA. 305:2295–2302. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
van Altena AM, Kolwijck E, Spanjer MJ,
Hendriks JC, Massuger LF and de Hullu JA: CA125 nadir concentration
is an independent predictor of tumor recurrence in patients with
ovarian cancer: A population-based study. Gynecol Oncol.
119:265–269. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Jayson GC, Kohn EC, Kitchener HC and
Ledermann JA: Ovarian cancer. Lancet. 384:1376–1388. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Piatek S, Panek G, Lewandowski Z, Piatek
D, Kosinski P and Bidzinski M: Nadir CA-125 has prognostic value
for recurrence, but not for survival in patients with ovarian
cancer. Sci Rep. 11:181902021. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Bates M, Mohamed BM, Lewis F, O'Toole S
and O'Leary JJ: Biomarkers in high grade serous ovarian cancer.
Biochim Biophys Acta Rev Cancer. 1879:1892242024. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Markman M: Optimizing primary chemotherapy
in ovarian cancer. Hematol Oncol Clin North Am. 17:957–968. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vergote I, Tropé CG, Amant F, Kristensen
GB, Ehlen T, Johnson N, Verheijen RH, van der Burg ME, Lacave AJ,
Panici PB, et al: Neoadjuvant chemotherapy or primary surgery in
stage IIIC or IV ovarian cancer. N Engl J Med. 363:943–953. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kehoe S, Hook J, Nankivell M, Jayson GC,
Kitchener H, Lopes T, Luesley D, Perren T, Bannoo S, Mascarenhas M,
et al: Primary chemotherapy versus primary surgery for newly
diagnosed advanced ovarian cancer (CHORUS): An open-label,
randomised, controlled, non-inferiority trial. Lancet. 386:249–257.
2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Denkert C, Loibl S, Müller B, Eidtmann H,
Schmitt W, Eiermann W, Gerber B, Tesch H, Hilfrich J, Huober J, et
al: Ki67 levels as predictive and prognostic parameters in
pretherapeutic breast cancer core biopsies: A translational
investigation in the neoadjuvant GeparTrio trial. Ann Oncol.
24:2786–2793. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Qi X, Zhang F, Wu H, Liu J, Zong B, Xu C
and Jiang J: Wilms' tumor 1 (WT1) expression and prognosis in solid
cancer patients: A systematic review and meta-analysis. Sci Rep.
5:89242015. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Reuschenbach M, Rafiyan M, Karbach J,
Pauligk C, Faulstich F, Sauer M, Prigge ES, Kloor M, Al-Batran S,
Kaufmann AM, et al: Phase I/IIa study of therapeutic p16INK4a
vaccination in patients with HPV-associated cancers. J Clin Oncol.
32:3092–3097. 2014. View Article : Google Scholar
|
|
24
|
Rice JC, Ozcelik H, Maxeiner P, Andrulis I
and Futscher BW: Methylation of the BRCA1 promoter is associated
with decreased BRCA1 mRNA levels in clinical breast cancer
specimens. Carcinogenesis. 21:1761–1765. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
National Comprehensive Cancer Network.
NCCN Clinical Practice Guidelines in Oncology, . Ovarian Cancer,
version 1.2023. National Comprehensive Cancer Network; 2023,
https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1453February
15–2025
|
